How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

OBJECTIVE: In rare disease research, most randomized prospective clinical trials can only use limited number of patients and are comprised of highly heterogeneous populations. Therefore, it is crucial to report the results in such a manner that it allows for comparison of treatment effectiveness and...

Descripción completa

Detalles Bibliográficos
Autores principales: van Esdonk, Michiel J., van Zutphen, Eline J. M., Roelfsema, Ferdinand, Pereira, Alberto M., van der Graaf, Piet H., Biermasz, Nienke R., Stevens, Jasper, Burggraaf, Jacobus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942341/
https://www.ncbi.nlm.nih.gov/pubmed/29605877
http://dx.doi.org/10.1007/s11102-018-0884-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942341/
https://www.ncbi.nlm.nih.gov/pubmed/29605877
http://dx.doi.org/10.1007/s11102-018-0884-4

Ejemplares similares